High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? a preliminary study

Clinical Infectious Diseases

Volumn 54, Issue 12, 2012, Pages 1720-1726

  Dalfino, Lidia ^a   Puntillo, Filomena ^a   Mosca, Adriana ^a   Monno, Rosa ^a   Spada, Maria Luigia ^a   Coppolecchia, Sara ^a   Miragliotta, Giuseppe ^a   Bruno, Francesco ^a   Brienza, Nicola ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIMETHATE; COLISTIN; CREATININE; GENTAMICIN; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD SAMPLING; BLOODSTREAM INFECTION; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; LUNG ASPIRATION; MAINTENANCE DRUG DOSE; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS INFECTION; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SERRATIA MARCESCENS; TREATMENT RESPONSE; URINALYSIS; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COLISTIN; CRITICAL ILLNESS; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME;

EID: 84861503214     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis286     Document Type: Article

References (39)

1. Shorr AF. Review of studies of the impact on gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009; 37:1463-9.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
3. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
4. Catchpole CR, Andrews JM, Brenwald N, et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39:255-60. (Pubitemid 27116423)
5. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115-21. (Pubitemid 40259694)
6. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31:1058-65. (Pubitemid 41125336)
7. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulfonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35:297-300.
8. Kasiakou S, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis. Antimicrob Agents Chemother 2005; 49:3136-46. (Pubitemid 41060551)
9. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez J, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilatorassociated-pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8. (Pubitemid 36549630)
10. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11. (Pubitemid 29203530)
11. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of Parenteral Colistin for the Treatment of Serious Infection Due to Antimicrobial-Resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154-60.
12. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25: 596-9. (Pubitemid 44379694)
13. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78-83.
14. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33:1162-7. (Pubitemid 47036903)
15. Michalopoulos AS, KaratzaDC,Gregorakos L. Pharmacokinetic evaluation of colistin sodium. Expert Opin Drug Metab Toxicol 2011; 7:245-55.
16. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011; 11:464-9.
17. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30:143-51. (Pubitemid 351834728)
18. Daikos GL, Skiada A, Pavleas J, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010; 22:175-8.
19. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010; 138:1333-9.
20. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
21. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6.
22. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32. (Pubitemid 351763841)
23. Niederman MS, Craven DE, Bonten MJ, et al. American Thoracic Society and the Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
24. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee. Definition for sepsis and organ failures and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth information supplement. Wayne, PA: CLSI, 2007 [Document M100-S17].
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-266.
27. Bagshaw SM, George C, Bellomo R, for the ANZICS Database Management Committe. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23:1569-74. (Pubitemid 351767782)
28. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64:i3-10.
29. Klompas M. Does this patient have ventilator-associated pneumonia? JAMA 2007; 297:1583-93. (Pubitemid 46588372)
30. Ko H, Jeon M, Choo E, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117:c284-8.
31. Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35:473-7.
32. Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol 1996; 154:119-30. (Pubitemid 26413995)
33. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004; 286:C913-22. (Pubitemid 38543820)
34. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724-8.
35. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26:504-7. (Pubitemid 41635502)
36. Ratranaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011; 62:187-90.
37. Sorli L, Luque S, Grau S, et al. Colistin minimum plasma concentration is an independent risk factor for nephrotoxicity. Clin Microbiol Infect special issue: abstracts of the 21st ECCMID/27th ICC, Milan, Italy, 7-10 May 2011; 17:S16. Abstract O86.
38. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infct Dis 2007; 45:753-60. (Pubitemid 47378891)
39. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14:816-27.